report claims Novo Nordisk's semaglutide 2 mg dose reduced the risk of serious cardiovascular events by 6%. No study details or confirmation are available.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
